Breaking News

Amgen Inc. v. Sanofi

Petition for certiorari denied on January 7, 2019
Docket No. Op. Below Argument Opinion Vote Author Term
18-127 Fed. Cir. N/A N/A N/A N/A OT 2018

Issue: Whether the standard for determining the adequacy of the “written description of the invention” in a patent must be “in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains . . . to make and use the same,” as stated within the Patent Act, 35 U.S.C. § 112(a), or whether court-created standards should control instead.

SCOTUSblog Coverage

DateProceedings and Orders (key to color coding)
May 11 2018Application (17A1262) to extend the time to file a petition for a writ of certiorari from May 24, 2018 to July 23, 2018, submitted to The Chief Justice.
May 14 2018Application (17A1262) granted by The Chief Justice extending the time to file until July 23, 2018.
Jul 23 2018Petition for a writ of certiorari filed. (Response due August 27, 2018)
Aug 27 2018Brief amici curiae of Bristol-Myers Squibb Company, Morphosys AG, Bavarian Nordic A/S, and UCB Biopharma SPRL filed.
Sep 12 2018DISTRIBUTED for Conference of 10/5/2018.
Sep 18 2018Response Requested. (Due October 18, 2018)
Sep 20 2018Motion to extend the time to file a response is granted and the time is extended to and including November 19, 2018
Sep 20 2018Motion to extend the time to file a response from October 18, 2018 to November 17, 2018, submitted to The Clerk.
Nov 19 2018Brief of respondents Sanofi, et al. in opposition filed.
Dec 04 2018Reply of petitioners Amgen Inc., et al. filed. (Distributed)
Dec 05 2018DISTRIBUTED for Conference of 1/4/2019.
Jan 07 2019Petition DENIED.